Saliva-Based Biomarkers for Non-Invasive Assessment of Pediatric Gastrointestinal Inflammatory Diseases: Current Evidence and Future Perspectives
Children · 19.11.2026 · 13 (11) · 1608
DOI: 10.3390/children13111608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 19.11.2026. Verfasst von Andrea Scavella und 3 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Endoscopy with biopsy remains central to the diagnosis and assessment of pediatric inflammatory bowel disease (IBD), eosinophilic esophagitis (EoE), and celiac disease (CD). However, its invasive nature, procedural burden, cost, and limited suitability for repeated assessment highlight the need for non-invasive biomarkers in children. This review critically evaluates the current evidence for saliva-based biomarkers in these disorders.
Methods
A critical narrative literature search was performed in PubMed/MEDLINE and Scopus to identify studies on salivary biomarkers in pediatric IBD, EoE, and CD. Pediatric evidence was prioritized; adult studies were included only when pediatric data were unavailable or limited, and were explicitly distinguished from pediatric findings.
Results
Saliva offers major practical advantages in children because collection is painless, inexpensive, repeatable, and feasible without venipuncture or sedation. However, salivary profiles are influenced by oral health, diet, collection procedures, and other pre-analytical factors. In IBD, pediatric evidence remains limited and heterogeneous, with preliminary signals from salivary calprotectin, microbiome, and high-dimensional proteomics. In EoE, salivary microRNAs, volatile organic compounds, and selected microbial taxa show promising but exploratory results, mainly in small cohorts. In CD, salivary anti-tissue transglutaminase IgA has the most interesting pediatric evidence, including data from population-based screening studies.
Conclusions
Saliva cannot currently replace established diagnostic tools. The level of evidence varies substantially across diseases: salivary anti-tTG IgA has the most substantial paediatric evidence and may have a complementary role in population-based screening, whereas findings in IBD and EoE remain largely exploratory. Future studies should prioritise methodological standardisation, prospective multicentre validation and direct comparisons with established diagnostic and monitoring standards.
Zitieren
APA
Scavella, A., Salvatore, S., D’Antiga, L., & Sansotta, N. (2026). Saliva-Based Biomarkers for Non-Invasive Assessment of Pediatric Gastrointestinal Inflammatory Diseases: Current Evidence and Future Perspectives. Children, 13(11), 1608. https://doi.org/10.3390/children13111608
Vancouver
Scavella A, Salvatore S, D’Antiga L, Sansotta N. Saliva-Based Biomarkers for Non-Invasive Assessment of Pediatric Gastrointestinal Inflammatory Diseases: Current Evidence and Future Perspectives. Children. 2026;13(11):1608. doi:10.3390/children13111608
BibTeX
@article{Scavella2026,
author = {Scavella, Andrea and Salvatore, Silvia and D’Antiga, Lorenzo and Sansotta, Naire},
title = {Saliva-Based Biomarkers for Non-Invasive Assessment of Pediatric Gastrointestinal Inflammatory Diseases: Current Evidence and Future Perspectives},
journal = {Children},
year = {2026},
volume = {13},
number = {11},
pages = {1608},
doi = {10.3390/children13111608}
}
EUVIMED